A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Featured News
EU’s Largest Economies Push to Reduce Reliance on Foreign Payment Systems
Mar 12, 2026 by
CPI
Warren Presses Amazon for Answers on Pricing Practices for Government Buyers
Mar 12, 2026 by
CPI
EU Antitrust Chief Raises Concerns Over Big Tech Control of AI
Mar 12, 2026 by
CPI
Burson Adds Senior Advisor to Strengthen Competition Team
Mar 12, 2026 by
CPI
South Korea Fines Pork Processors for Price-Fixing in Retail Supply Deals
Mar 12, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece